New ABPI Guidance on joint working between UK pharma companies and NHS

The UK's National Health Service is changing rapidly and there is a desire on the part of government and the NHS for the the latter to  engage with the pharmaceutical industry on a broader agenda, says  Martin Anderson, director NHS policy and partnership at the Association  of the British Pharmaceutical Industry, writing for the Pharma  Marketletter. An underlying principle for joint working between the NHS  and the pharmaceutical industry must be that it brings benefits to  patients. Transparency and openness are key considerations to the  implementation of appropriate joint working, he stresses.

The ABPI has introduced guidance to provide a framework and greater  clarity for pharmaceutical companies about various aspects of joint  working between the drug industry and the NHS.

Background